Regenerative Medical Technology (RMTG) Other Accumulated Expenses (2021 - 2022)
Regenerative Medical Technology (RMTG) posted quarterly Other Accumulated Expenses of $10000.0 for Q1 2022, down 50.0% quarter-over-quarter from $20000.0 in Q4 2021.
Regenerative Medical Technology (RMTG) Other Accumulated Expenses (2021 - 2022) Analysis & Trends
Regenerative Medical Technology's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $10000.0 for Q1 2022.
- In Q1 2022, Other Accumulated Expenses changed N/A year-over-year to $10000.0; the TTM figure through Mar 2022 stood at $10000.0 (changed N/A YoY), while the FY2021 annual figure was $20000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q1 2022 stood at $10000.0, down from $20000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $251536.0 in Q3 2021, with the low at $10000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 251,536.00 |